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Abstract
Background: HIV-1 RNA load is the best biological predictor of HIV transmission and 
treatment response. The rate of virologic suppression among key sub-populations can guide HIV 
prevention programs.
Methods: The Botswana Combination Prevention Project performed a population-based 
household survey among adults in 30 communities in Botswana. Data collected included 
knowledge of HIV-positive status, ART coverage and virologic suppression (HIV-1 RNA ≤400 
copies/mL). Individuals aged 16–29 years were considered young adults.
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Results: Among 552 young people living with HIV (PLHIV) enrolled with RNA load data and 
ART status available, 51% (n=279) had undetectable HIV-1 RNA, including 54% of young women 
and 32% of young men (gender PR: 0.53; 95% CI: 0.43–0.80; p<0.001). Compared with older 
adults (30–64 years old), young HIV-infected adults were significantly less likely to have 
undetectable HIV-1 RNA (PR: 0.65; 95%CI: 0.59–0.70; p<0.0001), including both men (PR: 0.43; 
95%CI: 0.34–0.56; p<0.0001) and women (PR: 0.67; 95%CI: 0.62–0.74; p<0.0001). Among a 
subset of PLHIV receiving ART, young adults also were less likely to have undetectable HIV-1 
RNA load than older adults (PR: 0.93; 95%CI: 0.90–0.95; p=<0.0001). Analysis of the care 
continuum revealed that inferior HIV diagnosis and sub-optimal linkage to care are the primary 
reasons for low virologic suppression among young adults.
Conclusions: Young adults in Botswana are significantly less likely to have undetectable HIV-1 
RNA load compared with older adults. In the era of broad scale-up of ART, interventions able to 
diagnose young adults living with HIV and link them to effective therapy are urgently needed.
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Introduction
Increased access to HIV treatment has saved millions of lives and reduced HIV 
transmissions.1–3 Southern African countries have adopted the World Health Organization 
(WHO) recommendations to provide antiretroviral therapy (ART) to all HIV-infected 
individuals,4 as an important move toward ending the HIV epidemic. To optimize health and 
HIV transmission prevention outcomes, the Joint United Nations Program on HIV/AIDS 
(UNAIDS) has established new targets aimed at ending the AIDS epidemic: by 2020, 90% 
of all people living with HIV (PLHIV) should know their HIV status, 90% of those 
diagnosed with HIV infection should receive sustained combination ART, and 90% of all 
people receiving ART should have viral suppression (“90–90-90”).5
Botswana is in the midst of a generalized HIV epidemic with an estimated 24.3% of the 
adult population (15–49 years) living with HIV.6 In 2002, experiencing a devastating burden 
of epidemic HIV infection, Botswana initiated a national ART program (free to all citizens). 
The successful scale-up of the ART program has resulted in Botswana’s approaching the 
UNAIDS 90–90-90 goals.7,8 By the end of 2015, based on a population-based survey, 83% 
of PLHIV aged 16–64 years old residing in 30 Botswana peri-urban communities knew their 
HIV status, 87.4% of them were receiving ART, and 96% of people on ART had 
undetectable HIV-1 RNA.8 Despite this impressive achievement, new HIV transmissions are 
still occurring in the same communities, and HIV-1 incidence in adults in Botswana is 
estimated at 1.0–1.35%.9,10
High HIV incidence and prevalence among young women remains a hallmark of the HIV-1C 
epidemic in sub-Saharan Africa.11–13 Young women and men in Africa represent the 
populations most in need of treatment services.14 Younger age in discordant couples in 
Kenya and Uganda has been found to be associated with delayed ART initiation, failure to 
achieve viral suppression, and increased risk of virologic rebound.15,16 In a study conducted 
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in Chicago, 46 adolescents and young adults had lower rates of virologic suppression, and 
higher rates of loss to follow-up compared with 46 older PLHIV.17 Studies in South Africa 
demonstrated that rapid ART initiation is acceptable and feasible, and increases uptake, 
although rapid initiation of ART among men and younger adults is challenging.18,19 The 
population level rates of virologic suppression among young adults in Southern Africa 
remain unknown.
Early and durable suppression of viral replication evident by undetectable levels of HIV-1 
RNA should be the ultimate goal of public health interventions. The population level of viral 
suppression is depicted by the third “90” of the UNAIDS goals5, an approach that helps to 
prioritize public health strategies and interventions. However, rates of ART coverage and 
virologic suppression among some key sub-populations in Africa remain unknown, 
particularly for young PLHIV.
In this study we focused on PLHIV in 30 communities in Botswana and performed the 
following analyses: assessed attainment of the “90–90-90” UNAIDS goals5 among young 
(aged 16–29 years) and older (aged 30–64 years) adults in Botswana, estimated HIV 
prevalence stratified by age and gender, evaluated the proportions of individuals currently on 
ART by age and gender, and estimated the extent of virologic suppression by age and 
gender.
Methods
Ethical approval
The study was approved by the Botswana Health Research and Development Committee 
(Institutional Review Board of the Botswana Ministry of Health and Wellness) and the US 
Centers for Disease Control and Prevention Institutional Review Board. All participants 
provided written informed consent (or assent with guardian permission, in the case of 
persons at least 16 but less than 18 years of age).
Study participants
The Botswana Combination Prevention Project (BCPP; also known as the “Ya Tsie” study) 
is an ongoing pair-matched, cluster-randomized clinical trial in which 15 community pairs 
were randomized 1:1 to test whether a combination HIV prevention intervention package is 
able to reduce cumulative 3-year HIV incidence on a population level, as compared with the 
enhanced national standard of care. Targeted communities were matched in pairs by size, 
health services, population age structure, and geographic location. The baseline household 
survey (BHS) enrolled a random, population-based sample of approximately 20% of 16–64-
year-old residents between October 2013 and November 2015. The approach to selecting 
and enrolling the 20% random sample has been previously described. 8 Survey staff 
performed HIV testing and counseling (HTC), provided point-of-care (POC) CD4 testing, 
collected blood from PLHIV for HIV-1 RNA testing and viral genotyping, evaluated uptake 
of HTC, and assessed ART and male circumcision coverage. Only Botswana citizens were 
eligible to consent to study participation.
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During the household visits, eligible residents were asked to sign a written consent form to 
participate; to complete an individual questionnaire with socio-demographic and HIV-related 
information, including history of their HIV testing, ART status, and patterns of sexual 
behavior; and to donate a blood sample for a rapid HIV test (if no documentation on a 
previous HIV-positive test was available). Newly diagnosed and ART-naïve PLHIV were 
offered POC CD4 testing, and were asked to donate about 10 mL of blood for HIV-1 RNA 
testing and viral genotyping (venous blood was collected by phlebotomy in households). 
PLHIV in the control communities were referred to the Botswana national ART program 
(free-of-charge treatment for all adults with CD4 ≤350 cells/μL or WHO Stage III/IV at the 
time of the initial survey in 2013–2015). PLHIV in the intervention communities were 
referred to local government clinic to receive a package of interventions according to the 
study protocol. Services for pregnant women were focused on identification of HIV-infected 
pregnant women and strengthening their linkage to care, initiation of treatment and retention 
on ART post-delivery. HIV re-testing during the third trimester was enhanced for pregnant 
women with a previous HIV-negative test. Participants in the baseline household survey 
received a BWP 20 (approximately US $2) cellular-telephone prepaid voucher.
HIV testing
Participants who self-reported HIV-positive status and provided documentation, such as, 
written test results, or ART prescription, were not retested for HIV. All other participants 
were offered counselling and testing for HIV. HIV testing was performed in the household 
using Botswana HIV Testing guidelines,20 which include two rapid tests in parallel: KHB 
(KHB, Shanghai Kehua Bio-Engineering Co Ltd, China) and Unigold (Trinity Biotech Plc, 
Wicklow, Ireland). Only concordant results in both tests were considered valid. If results 
were discordant, confirmatory HIV testing was performed at a reference laboratory using 
EIA (Murex HIV 1.2.0 test, Murex Biotech Ltd, Dartford, Kent, England; or Biorad Genetic 
Systems™ HIV-1/HIV-2 PLUS O, BioRad, Redmond, WA; and/or Genetic Systems HIV-1 
Western Blot, Bio-Rad Laboratories, Redmond, WA). The results of the EIA and/or Western 
Blot superseded the discordant or indeterminate results obtained in the field.
HIV-1 RNA testing
Venous blood was collected by phlebotomy in households during the baseline survey and 
was processed in a mobile clinic within 4 hours from sampling. HIV-1 RNA was quantified 
in all PLHIV enrolled. The completeness of HIV-1 RNA testing was 99.7%. HIV-1 RNA 
load was quantified by Abbott m2000sp/Abbott m2000rt (Abbott Laboratories, Wiesbaden, 
Germany) at the Botswana-Harvard HIV Reference Laboratory, which is accredited by the 
South African National Accreditation System (SANAS) for HIV-1 viral load testing (ISO 
17025) and participates in Rush University’s Virology Quality Assurance program. HIV-1 
RNA load >400 copies/mL was considered detectable.
Statistical analysis
To assess coverage by the UNAIDS “90–90-90” targets5 by age and gender, this analysis 
used existing data from the baseline household survey in Botswana8. Women and men 16–
29 years old were defined as young adults, while individuals 30–64 years old were defined 
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as older adults. The numbers of study participants per group are presented in Supplementary 
Tables 1 and 2.
The first “90” is defined as documented previous knowledge of HIV-positive status. The 
second and the third 90’s were expressed with two denominators each. For the proportion of 
participants on ART, we used either all PLHIV, or only previously diagnosed HIV-positive 
participants (the second UNAIDS target5), as denominators. For the proportion of 
participants with undetectable HIV-1 RNA, ≤400 copies/mL, we used either all PLHIV, or 
only previously diagnosed HIV-positive participants receiving ART (the third UNAIDS 
target5), as denominators. The analyses that include all PLHIV in the denominator are 
adjunctive; they are technically not part of the UNAIDS 90–90-90 estimates.
Modified Poisson generalized estimating equations (with robust standard errors to account 
for within-community clustering) were used to estimate prevalence ratios (PR) and 95% 
confidence intervals (CI) for the following binary outcomes: HIV infection status, prior 
knowledge of HIV-positive status, documented receipt of antiretroviral therapy, and 
undetectable HIV-1 RNA load (≤400 copies/mL). Estimated HIV prevalence and 95% CI 
according to age (16–29 years vs. 30–64 years) and gender were calculated by fitting an 
intercept-only logistic regression model with generalized estimating equations (GEE) 
accounting for clustering by community. All analyses were conducted using SAS software 
version 9.4 (SAS Institute, Cary, NC) and R version 3.3.1.21
Results
We recently reported on Botswana’s achievement of high rates of HIV testing, treatment 
coverage, and virologic suppression overall.8 However, in the current analysis by age, we 
found that the proportion of young PLHIV aware of their HIV infection (the first 90 in the 
UNAIDS targets5) was 66%, which is lower than among older adults (87%; Figure 1A; see 
Supplementary Table 1 for the number of participants in each group). The proportion of 
young adults diagnosed with HIV infection on ART (second 90) was 75%, which is lower 
than among older adults (89%; Figure 1A). The proportion of diagnosed young adults on 
ART with undetectable HIV-1 RNA (third 90) was 90%, which is also lower than among 
older adults (97%; Figure 1A). Among all PLHIV, the proportion of young adults on ART 
was 49% vs. 77% in older adults. Similarly, the proportion of virologically suppressed 
young adults was 44% among all PLHIV vs. 75% in older adults (Figure 1A).
Compared with older men, fewer young men knew about their positive HIV status (45% vs. 
81%; 1st 90); they were less likely to be on ART (32% vs. 73%; Proportion of all men living 
with HIV who are on ART), and were less likely to have undetectable HIV-1 RNA (24% vs. 
71%; Proportion of all men living with HIV who are virologically suppressed; Figure 1B). A 
similar pattern was found among young women (Figure 1C). As compared with older 
women, a smaller proportion of young women were aware of their HIV infection (70% vs. 
89%); young women were less likely to be receiving ART (52% vs. 79% among all women 
living with HIV), and fewer of them had undetectable HIV-1 RNA (48% vs. 77% among all 
women living with HIV; Figure 1C).
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Compared with older adults (30–64 years old), young HIV-infected adults were significantly 
less likely to have undetectable HIV-1 RNA (PR: 0.65; 95%CI: 0.59–0.70; p<0.0001), 
including both men (PR: 0.43; 95%CI: 0.34–0.56; p<0.0001) and women (PR: 0.67; 95%CI: 
0.62–0.74; p<0.0001). Among a subset of PLHIV receiving ART, young adults also were 
less likely to have undetectable HIV-1 RNA load than older adults (PR: 0.93; 95%CI: 0.90–
0.95; p=<0.0001).
Reducing the age cut-off from 30 years to 25 years resulted in similar proportions across all 
comparisons. Compared with older adults (25–64 years old), young HIV-infected adults 
were significantly less likely to have undetectable HIV-1 RNA (PR: 0.59; 95%CI: 0.52–
0.68; p<0.0001), including both men (PR: 0.41; 95%CI: 0.26–0.65; p<0.0001) and women 
(PR: 0.62; 95%CI: 0.53–0.73; p<0.0001). Among a subset of PLHIV receiving ART, young 
adults also were less likely to have undetectable HIV-1 RNA load than older adults (PR: 
0.87; 95%CI: 0.82–0.92; p=<0.0001).
HIV prevalence
We found a substantial gender gap in HIV prevalence across 30 villages in Botswana. 
Among men aged 16–64 years, 21% (95% CI: 19%–23%) were HIV-infected. Among 
women of the same age, 33% (95% CI: 30%–35%) were infected (P<0.0001).
Figure 2A demonstrates HIV prevalence by age group (see Supplementary Table 2 for the 
number of participants in each group). HIV-1 prevalence among women started to rise 
during teenage years, and gradually increased with age, exceeding 50% in women aged 35–
49 years. HIV prevalence in men remained under 10% until age 30, and then gradually 
increased to levels close to 50% in men 40–49 years.
Knowledge of HIV-positive status
Knowledge of HIV-positive status by age group (Figure 2B) was similar to the HIV 
prevalence graph (Figure 2A). In women aged 16 to 24 years, awareness of positive HIV 
status was approximately 60% and gradually increased with age (Figure 2B). Knowledge of 
HIV-positive status was particularly low (below 50%) among men 20–29 years old. Young 
PLHIV were less likely to be aware of their positive HIV status compared with older adults 
(PR: 0.76; 95% CI: 0.71–0.80; P<0.0001).
PLHIV receiving ART
Stratified by age and gender, the distribution of individuals on ART revealed that younger 
age was associated with not receiving ART (Figures 3A and 3B; see Supplementary Table 2 
for the number of participants in each group). Young HIV-infected men and women were 
significantly less likely to be on ART, compared with older adults (PR 0.63; 95% CI: 0.57–
0.69; p<0.0001).
The proportions of HIV-infected individuals receiving ART gradually increased with age 
(Figure 3A). Among HIV-positive men over 50 years old, ≥84% were receiving ART. About 
50% of young women living with HIV were receiving ART. In contrast, at least 76% of 
women over 35 years old were on ART.
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Figure 3B is restricted to PLHIV who tested HIV-positive in the past and already knew about 
their positive HIV status at the time of household visit. Young PLHIV were significantly less 
likely to be on ART, compared with older adults (PR 0.84; 95% CI: 0.79–0.89; p<0.0001). A 
comparison of Figures 3A andFigures 3B highlights that once diagnosed and initiated ART, 
there are no gender differences in those who remain on ART.
PLHIV with HIV-1 RNA load ≤400 copies/mL
Younger age was associated with having detectable HIV-1 RNA (Figure 4A; see 
Supplementary Table 2 for the number of participants in each group). Among young men 
living with HIV, only 35% in the age group 16–19 years old, 26% in the age group 20–24 
years old and 36% in the age group 25–29 years old had HIV-1 RNA ≤400 copies/mL. The 
proportion of men living with HIV having undetectable HIV-1 RNA load gradually 
increased with age. More than 84% of men over 50 years old had undetectable HIV-1 RNA. 
The proportion of virologically suppressed women gradually increased across young age 
groups and plateaued in the range of 81%–86% after 35 years of age (decreasing to 77% in 
the age group 60–64 years).
Young PLHIV were significantly less likely to have undetectable HIV-1 RNA load (PR: 
0.57; 95% CI: 0.52–0.63; p<0.0001). Young men were less likely to have undetectable 
HIV-1 RNA compared to older men (PR: 0.37; 95% CI: 0.29–0.48; p<0.0001).
Figure 4B shows the proportion of PLHIV with undetectable HIV-1 RNA load among those 
who were previously diagnosed and receiving ART. Remarkably, all individuals in the oldest 
age groups had undetectable HIV-1 RNA load. Within the subset of previously diagnosed 
individuals receiving ART, young adults were less likely to have undetectable HIV-1 RNA 
load than older adults (PR: 0.93; 95%CI: 0.90–0.95; p<0.0001).
We found a subset of young HIV-infected adults (7 men and 29 women) who reported no use 
of ART, but had undetectable HIV-1 RNA, and therefore fell out of the care continuium 
scheme, as they were not included in the second 90. Accounting for these virologically 
suppressed individuals, effectively increased the proportion of young PLHIV with 
undetectable HIV-1 RNA to 51%.
Discussion
This study highlights that despite the overall success of the national ART program among 
the general population in Botswana,8 coverage by the UNAIDS 90–90-90 targets remains 
significantly lower among young people aged 16–29 years living with HIV in Botswana. 
The lowest coverage was found among young men – only 24% of men living with HIV aged 
16–29 years had undetectable HIV-1 RNA load. Overall, 55% of young PLHIV surveyed 
had detectable HIV-1 RNA and were at risk for transmitting the virus to others. Results from 
this analysis should inform public health policy in Botswana and assist in prioritizing HIV 
prevention interventions in the country.
Importantly, elevated prevalence of viremia in young adults does not appear to be primarily 
related to poorer ART adherence or retention. Young adults on ART were 7% less likely to 
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have achieved virologic suppression than older individuals, suggesting lower adherence or 
retention. However, the predominant contributor to lack of virologic suppression among 
young adults was lack of knowledge that they had HIV, and decreased use of ART among 
those aware that they had HIV infection. Some other factors could also contribute to the 
elevated levels of HIV-1 RNA in young adults.
The observation of increased viremia prevalence among young adults can likely be attributed 
in part to ART guidelines at the time of the survey. At the time of the survey, HIV-infected 
people with CD4 count below 350, or with other indications for treatment, were eligible for 
ART 22. As HIV incidence peaks during the third decade of life, 23 young adults are more 
likely to have recently acquired HIV infection and consequently more likely to have a 
preserved CD4 cell count than older individuals. Therefore, young adults could be 
disproportionately affected by prior CD4-driven treatment ineligibility. It is likely that 
implementation and scale-up of the universal ART policy could improve engagement and 
access to ART among young PLHIV. However, lack of knowledge of HIV positive status in 
young adults remains a major barrier, particularly among men, even in the context of 
universal ART. A strong antenatal HIV testing program 24–29 has minimized undiagnosed 
HIV infection among young women in Botswana, but new programs effective with men are 
urgently needed.Targeted interventions, such as clinics focusing on young adults,30 or 
dedicated programs aimed at young PLHIV,31,32 could be critical components of national 
ART programs in southern Africa.
Additionally, reaching men is crucial for ultimate control of the HIV epidemic in southern 
Africa. To improve access to diagnosis and linkage to care, men-friendly environments 
including men peer campaigners and men-targeted HIV services are needed.33 To target 
men, comprehensive interventions should be partnered with community mobilization 
strategies and include a broad range of services, such as community-based testing, 
workplace testing, self-testing, and men-only facilities or men-only hours.34 In addition, 
community models of ART service delivery may be needed in communities where men do 
not access HIV care and treatment services in the facilities.
It is well known that PLHIV need to take ART in order to reach virologic suppression. 
However, virologic suppression among ART-naïve PLHIV (e.g., “elite”, or viremic 
controllers) has been reported previously 35–39. Some studies reported a high frequency of 
undetectable HIV-1 RNA among ART-naïve people 40,41. In this study 36 (7%; 95% CI 5–
9%) of young HIV-infected adults reported no use of ARV but had undetectable HIV-1 
RNA. It is possible that at least some of these individuals were taking ART. Accounting for 
young PLHIV who reported being ART-naive but who had undetectable HIV-1 RNA load 
effectively increased the overall proportion of virologically suppressed young adults to 51%. 
Although this estimate is not technically the 3rd 90 of the UNAIDS targets,5 we believe it is 
an important component of the ‘big picture’ of the HIV epidemic among young adults.
The study has limitations. The study results could be influenced by CD4-driven initiation of 
ART at the time of the survey, as this approach could disproportionately affect young HIV-
infected adults more likely to have shorter duration of HIV infection. Using overall 
knowledge of HIV-status, we analyzed prevalence of viral suppression. However, if a person 
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does not know they are HIV-infected or has not been referred for treatment, viral 
suppression is unlikely. While we highlight that detectable levels of HIV-1 RNA are more 
prevalent in young adults, merely testing those who are not aware of their HIV status may 
not be sufficient in achieving community viral suppression. The behaviors and beliefs of 
young adults in our cohort who were unaware of their HIV status may differ from those 
young adults aware of their HIV-positive status who pursued treatment. Therefore, 
programmatic public health strategies must evaluate and monitor the care cascade with a 
focus on identifying predictors of failure in order to best customize programming efforts for 
those least likely to achieve viral suppression and most likely to transmit virus.
The study demonstrates low coverage towards UNAIDS goals among young adults in 
Botswana, which is a health problem for young PLHIV and a challenge for overall HIV 
epidemic control. Young adults in Botswana may be contributing disproportionately to HIV-
transmission networks. The study results suggest that targeted interventions should be 
tailored to improve HIV testing, linkage to care and treatment coverage among young adults, 
and young men, in particular. Research on the dynamics of HIV transmission networks 
among young adults could inform more effective prevention programs.
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Figure 1. 
Proportions of PLHIV meeting the UNAIDS 90–90-90 targets, on ART, and virologically 
suppressed, overall by age and by gender in Botswana. Study participants were sampled in 
20% of households in 30 Botswana communities. See Supplementary Table 1 for the number 
of participants in each group. A: General population (total, both genders) is shown as the 
darkest gray bar. Young adults (16–29 years old) are shown as medium tone graybar. Older 
adults (30–64 years old) are presented as the lightest graybar. B: Men. The darkest gray bars 
indicate men of any age (16–64 years old). Medium tone gray bars show young men (16–29 
years old). The lightest gray bars delineate older men (30–64 years old). C: Women. The 
darkest gray bars indicate women of any age (16–64 years old). Medium tone gray bars 
show young women (16–29 years old). The lightest gray bars delineate older women (30–64 
years old).
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Figure 2. 
A: HIV prevalence among adults tested in 30 Botswana communities stratified by age and 
gender. B: Proportion of individuals aware of their positive HIV status stratified by age and 
gender. Women are represented by circles; men are represented by triangles. Dashed line in 
B denotes the first 90 in the UNAIDS targets.5 See Supplementary Table 2 for the number of 
participants in each group.
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Figure 3. 
A: Proportion of all PLHIV receiving ART in 30 Botswana communities, stratified by age 
and gender. Dashed line denotes the 81% target (0.90 × 0.90) among PLHIV. B: Proportion 
of previously diagnosed participants living with HIV currently on ART. Women are 
represented by circles; men are represented by triangles. Dashed line denotes the second 90 
in the UNAIDS targets.5 See Supplementary Table 2 for the number of participants in each 
group.
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Figure 4. 
A: Proportion of all PLHIV with undetectable HIV-1 RNA load (≤400 copies/mL) in 30 
Botswana communities, stratified by age and gender. Dashed line denotes the 73% target 
(0.90 × 0.90 × 0.90) among PLHIV. B: Proportion of PLHIV with undetectable HIV-1 RNA 
load among participants who were diagnosed previously and were receiving ART at the time 
of household visit. Women are represented by circles; men are represented by triangles. 
Dashed line denotes the third 90 in the UNAIDS targets.5 See Supplementary Table 2 for the 
number of participants in each group.
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